DigmBio
- Biotech or pharma, therapeutic R&D
DigmBio is a biotech startup established in April 2020. It is focused on developing small-molecule-based therapies with first-in-class potential. Our management team brings nearly a century of collective experience in small-molecule drug discovery and development. Our pipeline includes cancer therapy, a second-generation PARP1-selective inhibitor, and a CNS-related drug targeting Alzheimer's and Parkinson's diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}